Oramed Pharmaceuticals Inc.
NASDAQ:ORMPBiotechnology
+$0.03 today
- Market cap
- $169.16M
- Beta
- 1.24
- P/E (TTM)
- 1.4
- EPS (TTM)
- $2.70
- Dividend yield
- 6.54%
Volume 0.16M
Average 0.16M
ORMP Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Oramed Pharmaceuticals Inc.NASDAQ: ORMP
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q1 FY2026 net change in cash was -$32.75M, compared with $20.1M a year earlier. Trailing-twelve-month net change in cash was -$61.31M. Over 3 fiscal years it compounded at -38.7% a year.
Context
- Net change in cash amounted to 423.7% of revenue in FY2025.
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly net change in cash holds near -$32.75M or moves back toward the trailing-twelve-month quarterly average of -$15.33M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (8.47M) USD
- Year-over-year change
- -118.7%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8.47M) | -118.7% |
| FY2024 | 2024-12-31 | 45.37M | +244.4% |
| FY2023 | 2023-12-31 | (31.41M) | +14.6% |
| FY2022 | 2022-12-31 | (36.78M) | -163.5% |
| FY2021 | 2021-08-31 | 57.95M | — |
Net Change in Cash vs competitors
How ORMP compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -209.6% is the 9th highest of 10, against a peer median of +45.4%.
- Over three fiscal years its annual growth of -38.7% compares with a peer median of -39.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $79.05M USD | -221.2% | +105.0% | 50.3% | |
| LTM Mar 2026 | $72.93M USD | +856.8% | -54.9% | 1024.0% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $66.54M USD | — | — | — |
| LTM Mar 2026 | $61.31M USD | -209.6% | -38.7% | — | |
| FY2025 | $39.89M USD | +45.4% | -38.2% | 62323.4% | |
IMAImageneBio Inc | LTM Mar 2026 | $39.29M USD | +338.2% | — | — |
| LTM Mar 2026 | $34.82M USD | -143.9% | +26.2% | — | |
| LTM Mar 2026 | $29.52M USD | +295.4% | -58.6% | 2952.1% | |
| LTM Mar 2026 | €22.84M EUR | -203.0% | -73.8% | 77884.9% | |
| LTM Mar 2026 | $15.19M USD | +3411.8% | +74.6% | 191.4% | |
| LTM Mar 2026 | $3.89M USD | -67.3% | -39.8% | 2905.2% | |
| Peer median (excluding ORMP) | — | +45.4% | -39.0% | 2905.2% | |
Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Aug 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (22.24M) | (36.56M) | 5.53M | (19.06M) | 64.02M |
| Depreciation & Amortization | 77K | 58K | 196K | 193K | 121K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 7.91M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 5.99M |
| Change in Working Capital | (1.32M) | (943K) | (2.7M) | 3.2M | (1.91M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.06M | (376K) | (2.23M) | 3.53M | 1.13M |
| Other Working Capital | (3.38M) | (567K) | (471K) | (325K) | (3.04M) |
| Other Non-Cash Items | 2.3M | 8.75M | (13.32M) | 7.26M | (85.28M) |
| Operating Cash Flow | (21.18M) | (28.7M) | (10.3M) | (8.41M) | (9.15M) |
| Capital Expenditures | (375K) | (496K) | (254K) | (18K) | (1.93M) |
| Acquisitions (Net) | 1.5M | 24K | 0 | 0 | (7.25M) |
| Purchases of Investments | (53.82M) | (154.41M) | (190.92M) | (55.76M) | (88.51M) |
| Sales of Investments | 30.43M | 185.09M | 118.14M | 161.65M | 96.88M |
| Other Investing Activities | (1K) | 2K | 0 | (60K) | 6.25M |
| Investing Cash Flow | (22.26M) | 30.21M | (73.04M) | 105.82M | 5.44M |
| Debt Repayment | — | — | 49.55M | (49.55M) | 0 |
| Common Stock Issued | 101.39M | 11.56M | 2.43M | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | (2.48M) | (4.74M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | (2K) | 0 |
| Financing Cash Flow | 101.39M | 11.56M | 51.98M | (52.04M) | (4.74M) |
| Effect of Forex Changes | 2K | (49.85M) | (54K) | (4K) | (30K) |
| Net Change in Cash | 57.95M | (36.78M) | (31.41M) | 45.37M | (8.47M) |
| Free Cash Flow | (21.56M) | (29.2M) | (10.55M) | (8.43M) | (11.08M) |
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
Intrinsic Alpha fair value
Locked
Current Price
$3.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.